Antitumor vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond

Journal of Immunotherapy

Volumn 23, Issue 1, 2000, Pages 125-130

  Calbo, Sébastien ^a   Guichard, Gilles ^b   Muller, Sylviane ^b   Kourilsky, Philippe ^a   Briand, Jean Paul ^b   Abastado, Jean Pierre ^a,c  

^a INSERM   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

CTL; Immunoscope; Psedopeptide; Tumor

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PSEUDOPEPTIDE; T LYMPHOCYTE RECEPTOR; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; COMPUTER PROGRAM; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; TUMOR;

ANIMALS; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; FEMALE; H-2 ANTIGENS; MICE; MICE, INBRED DBA; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TRYPSIN; VACCINATION;

EID: 0033970468     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200001000-00015     Document Type: Article

References (21)

1. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
2. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-75.
3. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7:601-24.
4. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996;5:295-302.
5. Brown F. Synthetic peptides and purified antigens as vaccines. Int J Technol Assess Health Care 1994;10:161-6.
6. Widmann C, Maryanski JL, Romero P, Corradin G. Differential stability of antigenic MHC class I-restricted synthetic peptides. J Immunol 1991;147:3745-51.
7. Fauchère JL, Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res 1992;23:127-59.
8. Maryanski JL, Romero P, Van PA, et al. The identification of tyrosine as a common key residue in unrelated H-2Kd restricted antigenic peptides. Int Immunol 1991;3:1035-42.
9. Casanova J, Martinon F, Gournier H, et al. TCR selection by and recognition of two class I MHC-restricted antigenic peptides that differ at a single position. J Exp Med 1993;177:811-20.
10. Abastado JP, Darche S, Godeau F, Cami B, Kourilsky P. Intramolecular recombination between partially homologous sequences in Escherichia coli and Xenopus laevis oocytes. Proc Natl Acad Sci USA 1987;84:6496-500.
11. Varin N, Sautes C, Galinha A, Even J, Hogarth PM, Fridman WH. Recombinant soluble receptors for the Fc gamma portion inhibit antibody production in vitro. Eur J Immunol 1989;19:2263-8.
12. Colbère-Garapin F, Horodniceanu F, Kourilsky P, Garapin A. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 1981;150:1-4.
13. Graham FL, Eb van der AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456-67.
14. Guichard G, Benkirane N, Zeder-Lutz G, van Regenmortel MH, Briand JP, Muller S. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomirnetics. Proc Natl Acad Sci USA 1994;91: 9765-9.
15. Cerottini JC, Engers HD, Macdonald HR, Brunner T. Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J Exp Med 1974;140:703-17.
16. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA 1993;90:4319-23.
17. Jochum M, Machleidt W, Fritz H. Proteolysis-induced pathomechanisms in acute inflammation and related therapeutic approaches. In: Avilés FX, ed. Innovations in proteases and their inhibitors. New York: Walter de Gruyter, 1993;495-512.
18. Casanova JL, Maryanski JL. Antigen-selected T-cell receptor diversity and self-nonself homology. Immunol Today 1993;14: 391-4.
19. Bousso P, Casrouge A, Altman JD, et al. Individual variations in the murine T cell response to a specific peptide reflect variability in naive repertoires. Immunity 1998;9:169-78.
20. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995;4:337-60.
21. Edelman R. Adjuvants for the future. In: Levine M, Woodrow G, Cobon G, eds. New generation vaccines. New York: MArcel Dekker, 197:173-192.